Cargando…
Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights
Brexit was presented as an opportunity to promote innovation by breaking free from the European Union regulatory framework. Since the beginning of 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) has operated as the independent regulatory agency for the United Kingdom. The MHRA...
Autores principales: | Hofer, Matthias P., Criscuolo, Paola, Shah, Nilay, ter Wal, Anne L. J., Barlow, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797847/ https://www.ncbi.nlm.nih.gov/pubmed/36590956 http://dx.doi.org/10.3389/fmed.2022.1011082 |
Ejemplares similares
-
The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol
por: Milne-Ives, Madison, et al.
Publicado: (2020) -
The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018) -
Evaluating the impact of Brexit on the pharmaceutical industry
por: Kazzazi, Fawz, et al.
Publicado: (2017) -
Brexit and trade policy: an analysis of the governance of UK trade policy and what it means for health and social justice
por: van Schalkwyk, May C. I., et al.
Publicado: (2021) -
Regulatory strings that bind and the UK Parliament after Brexit
por: Jancic, Davor
Publicado: (2022)